Plain-English translation of NCT07557706 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing transcutaneous auricular vagus nerve stimulation (taVNS), a gentle, non-invasive technique that stimulates a nerve in your ear to help your body regulate heart rate and blood pressure. People with Parkinson's disease often struggle with these functions, which can make exercise and daily activities harder. Researchers hope this treatment could improve how your body naturally responds and help support your physical therapy and overall quality of life.
Heart rate and blood pressure control problems are common in Parkinson's disease and can limit physical activity and daily functioning. Researchers want to see if this non-invasive nerve stimulation could be a helpful tool to address these problems without medication or surgery.
You likely qualify if…
You likely don't qualify if…
You would visit the research center twice, at least 48 hours apart. During each visit, researchers will place a small stimulator on your ear for 15 minutes — one visit with active stimulation and one visit with a sham (inactive) version so they can compare the effects. The researchers will monitor your heart rate, blood pressure, and other body responses before, during, and after the stimulation to see how the treatment affects you.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States